Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer

A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).

(2017) H. A. Wakelee et al.   JOURNAL OF CLINICAL ONCOLOGY

Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).

(2017) R. J. Buckanovich et al.   JOURNAL OF CLINICAL ONCOLOGY

Resistance development after long-term sorafenib exposure in hepatocellular cancer cell lines and risk of rebound growth and epithelial to mesenchymal transition.

(2017) Chris Verslype et al.   JOURNAL OF CLINICAL ONCOLOGY

Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases

(2012) A. Tamburrino et al.   CLINICAL CANCER RESEARCH

Sorafenib therapy decreases the clearance of thyrotropin

(2012) Herman Verloop et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified Exon

(2012) A. Boichard et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

(2012) David C. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A233: Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone.

(2012) F. Schimmoller et al.   MOLECULAR CANCER THERAPEUTICS

Evidence of a Low Prevalence of RAS Mutations in a Large Medullary Thyroid Cancer Series

(2012) Raffaele Ciampi et al.   THYROID

Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors

(2012) Barbara Sennino et al.   Cancer Discovery

Synergistic Action of a RAF Inhibitor and a Dual PI3K/mTOR Inhibitor in Thyroid Cancer

(2011) N. Jin et al.   CLINICAL CANCER RESEARCH

Combined RET and Ki-67 assessment in sporadic medullary thyroid carcinoma: a useful tool for patient risk stratification

(2011) Caterina Mian et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

High Prevalence ofRASMutations inRET-Negative Sporadic Medullary Thyroid Carcinomas

(2011) Margarida M. Moura et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer

(2011) Razelle Kurzrock et al.   JOURNAL OF CLINICAL ONCOLOGY

Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer

(2011) Toni K. Choueiri et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Samuel A. Wells et al.   JOURNAL OF CLINICAL ONCOLOGY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes

(2010) Cristina Romei et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Sorafenib-Induced Hypothyroidism Is Associated with Increased Type 3 Deiodination

(2010) Randa M. Abdulrahman et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Increased Expression of Vascular Endothelial Growth Factor and Its Receptors, VEGFR-1 and VEGFR-2, in Medullary Thyroid Carcinoma

(2010) Clarissa Capp et al.   THYROID

Genetic Alterations in the Phosphoinositide 3-Kinase/Akt Signaling Pathway Confer Sensitivity of Thyroid Cancer Cells to Therapeutic Targeting of Akt and Mammalian Target of Rapamycin

(2009) D. Liu et al.   CANCER RESEARCH

Advances in Chemotherapy of Differentiated Epithelial and Medullary Thyroid Cancers

(2009) Steven I. Sherman   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

(2009) Richard T. Kloos (Chair) et al.   THYROID

Prognostic Significance of SomaticRETOncogene Mutations in Sporadic Medullary Thyroid Cancer: A 10-Year Follow-Up Study

(2007) Rossella Elisei et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM